Mylan to buy Agila Specialties from India's Strides for $1.6 bln
Feb 27 (Reuters) - Generic drugmaker Mylan Inc said it would buy Agila Specialties from India's Strides Arcolab Ltd for $1.6 billion to expand its injectable drugs business.
Mylan, one of the world's largest generic drugmakers with more than 1,100 products, said the acquisition is expected to immediately add to Mylan's adjusted diluted earnings per share following closing.
Mylan said the deal was unanimously approved by its board.
- Obama unveils U.S. immigration reform, setting up fight with Republicans |
- More arrests as protesters await Ferguson grand jury decision
- Henrik Fisker is back with a souped up Mustang
- Exclusive: U.S. increasing non-lethal military aid to Ukraine
- Russia warns U.S. against arms to Ukraine as Biden due in Kiev